EGFR inhibition protects cardiac damage and remodeling through attenuating oxidative stress in STZ-induced diabetic mouse model

Journal of Molecular and Cellular Cardiology

Volumn 82, Issue , 2015, Pages 63-74

  Liang, Dandan ^a   Zhong, Peng ^a,b   Hu, Jie ^a   Lin, Feng ^c   Qian, Yuanyuan ^a   Xu, Zheng ^a   Wang, Jingying ^a   Zeng, Chunlai ^b   Li, Xiaokun ^a   Liang, Guang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b LISHUI CENTRAL HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic cardiomyopathy; EGFR inhibitor; Epidermal growth factor receptor; Oxidative stress; ROS

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ACETYLCYSTEINE; AG 451; ANTIOXIDANT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLUCOSE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SHORT HAIRPIN RNA; STREPTOZOCIN; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; QUINAZOLINE DERIVATIVE; TYRPHOSTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DRUG EFFICACY; DRUG STRUCTURE; EMBRYO; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; CELL LINE; DIABETIC CARDIOMYOPATHIES; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; FIBROSIS; GLUCOSE BLOOD LEVEL; HEART MUSCLE; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

MUS; RATTUS;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BODY WEIGHT; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; FIBROSIS; MALE; MICE; MYOCARDIUM; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TYRPHOSTINS; VENTRICULAR REMODELING;

EID: 84924759050     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.02.029     Document Type: Article

References (36)

1. Forbes J.M., Cooper M.E. Mechanisms of diabetic complications. Physiol Rev 2013, 93:137-188.
2. Bugger H., Abel E.D. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014, 57:660-671.
3. Zhang Y., Babcock S.A., Hu N., Maris J.R., Wang H., Ren J. Mitochondrial aldehyde dehydrogenase (ALDH2) protects against streptozotocin-induced diabetic cardiomyopathy: role of GSK3beta and mitochondrial function. BMC Med 2012, 10:40.
4. Mandavia C.H., Aroor A.R., DeMarco V.G., Sowers J.R. Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci 2013, 92:601-608.
5. Saxena R., Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med Res Rev 2012, 32:166-215.
6. Akhtar S., Yousif M.H., Chandrasekhar B., Benter I.F. Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury. PLoS One 2012, 7:e39066.
7. Mormile R., De Michele M., Squarcia U., Quaini F. And what about epidermal growth factor (EGF) as the bridge between survivin and cardiac remodelling?. Int J Cardiol 2011, 148:116.
8. Kobayashi T., Eguchi S. The epidermal growth factor receptor: a missing link between endoplasmic reticulum stress and diabetic complication?. Hypertension 2012, 60:20-21.
9. Galan M., Kassan M., Choi S.K., Partyka M., Trebak M., Henrion D., et al. A novel role for epidermal growth factor receptor tyrosine kinase and its downstream endoplasmic reticulum stress in cardiac damage and microvascular dysfunction in type 1 diabetes mellitus. Hypertension 2012, 60:71-80.
10. 2+ cycling proteins, NADPH oxidase, poly (ADP-Ribose) polymerase and myosin heavy chain isozyme. Free Radic Biol Med 2006, 40:1419-1429.
11. Zhang M.-Z., Wang Y., Paueksakon P., Harris R.C. Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes 2014, 63:2063-2072.
12. Cai L., Wang Y., Zhou G., Chen T., Song Y., Li X., et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006, 48:1688-1697.
13. Wu D., Peng F., Zhang B., Ingram A., Gao B., Krepinsky J. Collagen I induction by high glucose levels is mediated by epidermal growth factor receptor and phosphoinositide 3-kinase/Akt signalling in mesangial cells. Diabetologia 2007, 50:2008-2018.
14. Belmadani S., Palen D.I., Gonzalez-Villalobos R.A., Boulares H.A., Matrougui K. Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 2008, 57:1629-1637.
15. Konishi A., Berk B.C. Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells. J Biol Chem 2003, 278:35049-35056.
16. Huynh K., Bernardo B.C., McMullen J.R., Ritchie R.H. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 2014, 142:375-415.
17. Wallace D.C. Mitochondrial genetics: a paradigm for aging and degenerative diseases?. Science 1992, 256:628-632.
18. Anderson E.J., Kypson A.P., Rodriguez E., Anderson C.A., Lehr E.J., Neufer P.D. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 2009, 54:1891-1898.
19. Ye G., Metreveli N.S., Donthi R.V., Xia S., Xu M., Carlson E.C., et al. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 2004, 53:1336-1343.
20. Lashin O.M., Szweda P.A., Szweda L.I., Romani A.M. Decreased complex II respiration and HNE-modified SDH subunit in diabetic heart. Free Radic Biol Med 2006, 40:886-896.
21. Turko I.V., Li L., Aulak K.S., Stuehr D.J., Chang J.-Y., Murad F. Protein tyrosine nitration in the mitochondria from diabetic mouse heart. Implications to dysfunctional mitochondria in diabetes. J Biol Chem 2003, 278:33972-33977.
22. Wei W., Liu Q., Tan Y., Liu L., Li X., Cai L. Oxidative stress, diabetes, and diabetic complications. Hemoglobin 2009, 33:370-377.
23. Shen X., Zheng S., Metreveli N.S., Epstein P.N. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006, 55:798-805.
24. Akhtar S., Benter I.F. The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. BioImpacts 2013, 3:5-9.
25. Takaguri A., Kimura K., Hinoki A., Bourne A.M., Autieri M.V., Eguchi S. A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature. Hypertension 2011, 57:841-845.
26. Chen J., Chen J.-K., Nagai K., Plieth D., Tan M., Lee T.-C., et al. EGFR signaling promotes TGFβ-dependent renal fibrosis. J Am Soc Nephrol 2012, 23:215-224.
27. Mormile R., De Michele M., Squarcia U., Quaini F. And what about epidermal growth factor (EGF) as the bridge between survivin and cardiac remodelling?. Int J Cardiol 2011, 148:116.
28. Krieg T., Cui L., Qin Q., Cohen M.V., Downey J.M. Mitochondrial ROS generation following acetylcholine-induced EGF receptor transactivation requires metalloproteinase cleavage of proHB-EGF. J Mol Cell Cardiol 2004, 36:435-443.
29. Chen X., Abair T.D., Ibanez M.R., Su Y., Frey M.R., Dise R.S., et al. Integrin α1β1 controls reactive oxygen species synthesis by negatively regulating epidermal growth factor receptor-mediated Rac activation. Mol Cell Biol 2007, 27:3313-3326.
30. Lien G.S., Wu M.S., Bien M.Y., Chen C.H., Lin C.H., Chen B.C. Epidermal growth factor stimulates nuclear factor-kappaB activation and heme oxygenase-1 expression via c-Src, NADPH oxidase, PI3K, and Akt in human colon cancer cells. PLoS One 2014, 9:e104891.
31. Nolly M.B., Caldiz C.I., Yeves A.M., Villa-Abrille M.C., Morgan P.E., Amado Mondaca N., et al. The signaling pathway for aldosterone-induced mitochondrial production of superoxide anion in the myocardium. J Mol Cell Cardiol 2014, 67:60-68.
32. Yang J., Li Q., Zhou X.D., Kolosov V.P., Perelman J.M. Naringenin attenuates mucous hypersecretion by modulating reactive oxygen species production and inhibiting NF-kappaB activity via EGFR-PI3K-Akt/ERK MAPKinase signaling in human airway epithelial cells. Mol Cell Biochem 2011, 351:29-40.
33. Kumar S., Kain V., Sitasawad S.L. Cardiotoxicity of calmidazolium chloride is attributed to calcium aggravation, oxidative and nitrosative stress, and apoptosis. Free Radic Biol Med 2009, 47:699-709.
34. Pan Y., Wang Y., Zhao Y., Peng K., Li W., Wang Y., et al. Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucose-induced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy. Diabetes 2014, 63:3497-3511.
35. Obana M., Miyamoto K., Murasawa S., Iwakura T., Hayama A., Yamashita T., et al. Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart. Am J Physiol Heart Circ Physiol 2012, 303:H569-H577.
36. Zeng C., Zhong P., Zhao Y., Kanchana K., Zhang Y., Khan Z.A., et al. Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-kappaB both in vitro and in vivo. J Mol Cell Cardiol 2015, 79:1-12.